Ophthalmology Disorders Drug Market

1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Oral
        1.2.3 Injection
        1.2.4 External Use
    1.3 Market by Application
        1.3.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
        1.3.3 Leber Congenital Amaurosis (LCA)
        1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
        1.3.5 Usher Syndrome
        1.3.6 Retinitis Pigmentosa (Retinitis)
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Ophthalmology Disorders Drug Market Perspective (2017-2028)
    2.2 Ophthalmology Disorders Drug Growth Trends by Region
        2.2.1 Ophthalmology Disorders Drug Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Ophthalmology Disorders Drug Historic Market Size by Region (2017-2022)
        2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Region (2023-2028)
    2.3 Ophthalmology Disorders Drug Market Dynamics
        2.3.1 Ophthalmology Disorders Drug Industry Trends
        2.3.2 Ophthalmology Disorders Drug Market Drivers
        2.3.3 Ophthalmology Disorders Drug Market Challenges
        2.3.4 Ophthalmology Disorders Drug Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Ophthalmology Disorders Drug Players by Revenue
        3.1.1 Global Top Ophthalmology Disorders Drug Players by Revenue (2017-2022)
        3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2017-2022)
    3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Ophthalmology Disorders Drug Revenue
    3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
        3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2021
    3.5 Ophthalmology Disorders Drug Key Players Head office and Area Served
    3.6 Key Players Ophthalmology Disorders Drug Product Solution and Service
    3.7 Date of Enter into Ophthalmology Disorders Drug Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmology Disorders Drug Breakdown Data by Type
    4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2017-2022)
    4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2023-2028)
5 Ophthalmology Disorders Drug Breakdown Data by Application
    5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2017-2022)
    5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Ophthalmology Disorders Drug Market Size (2017-2028)
    6.2 North America Ophthalmology Disorders Drug Market Size by Type
        6.2.1 North America Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        6.2.2 North America Ophthalmology Disorders Drug Market Size by Type (2023-2028)
        6.2.3 North America Ophthalmology Disorders Drug Market Share by Type (2017-2028)
    6.3 North America Ophthalmology Disorders Drug Market Size by Application
        6.3.1 North America Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        6.3.2 North America Ophthalmology Disorders Drug Market Size by Application (2023-2028)
        6.3.3 North America Ophthalmology Disorders Drug Market Share by Application (2017-2028)
    6.4 North America Ophthalmology Disorders Drug Market Size by Country
        6.4.1 North America Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        6.4.2 North America Ophthalmology Disorders Drug Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Ophthalmology Disorders Drug Market Size (2017-2028)
    7.2 Europe Ophthalmology Disorders Drug Market Size by Type
        7.2.1 Europe Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        7.2.2 Europe Ophthalmology Disorders Drug Market Size by Type (2023-2028)
        7.2.3 Europe Ophthalmology Disorders Drug Market Share by Type (2017-2028)
    7.3 Europe Ophthalmology Disorders Drug Market Size by Application
        7.3.1 Europe Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        7.3.2 Europe Ophthalmology Disorders Drug Market Size by Application (2023-2028)
        7.3.3 Europe Ophthalmology Disorders Drug Market Share by Application (2017-2028)
    7.4 Europe Ophthalmology Disorders Drug Market Size by Country
        7.4.1 Europe Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        7.4.2 Europe Ophthalmology Disorders Drug Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Ophthalmology Disorders Drug Market Size (2017-2028)
    8.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type
        8.2.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Ophthalmology Disorders Drug Market Share by Type (2017-2028)
    8.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application
        8.3.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Ophthalmology Disorders Drug Market Share by Application (2017-2028)
    8.4 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region
        8.4.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Ophthalmology Disorders Drug Market Size (2017-2028)
    9.2 Latin America Ophthalmology Disorders Drug Market Size by Type
        9.2.1 Latin America Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        9.2.2 Latin America Ophthalmology Disorders Drug Market Size by Type (2023-2028)
        9.2.3 Latin America Ophthalmology Disorders Drug Market Share by Type (2017-2028)
    9.3 Latin America Ophthalmology Disorders Drug Market Size by Application
        9.3.1 Latin America Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        9.3.2 Latin America Ophthalmology Disorders Drug Market Size by Application (2023-2028)
        9.3.3 Latin America Ophthalmology Disorders Drug Market Share by Application (2017-2028)
    9.4 Latin America Ophthalmology Disorders Drug Market Size by Country
        9.4.1 Latin America Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        9.4.2 Latin America Ophthalmology Disorders Drug Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Ophthalmology Disorders Drug Market Size (2017-2028)
    10.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type
        10.2.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Ophthalmology Disorders Drug Market Share by Type (2017-2028)
    10.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application
        10.3.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Ophthalmology Disorders Drug Market Share by Application (2017-2028)
    10.4 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country
        10.4.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Sanofi
        11.1.1 Sanofi Company Details
        11.1.2 Sanofi Business Overview
        11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
        11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.1.5 Sanofi Recent Developments
    11.2 Bayer
        11.2.1 Bayer Company Details
        11.2.2 Bayer Business Overview
        11.2.3 Bayer Ophthalmology Disorders Drug Introduction
        11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.2.5 Bayer Recent Developments
    11.3 Bausch + Lomb
        11.3.1 Bausch + Lomb Company Details
        11.3.2 Bausch + Lomb Business Overview
        11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
        11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.3.5 Bausch + Lomb Recent Developments
    11.4 Novartis
        11.4.1 Novartis Company Details
        11.4.2 Novartis Business Overview
        11.4.3 Novartis Ophthalmology Disorders Drug Introduction
        11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.4.5 Novartis Recent Developments
    11.5 Usher Syndrome
        11.5.1 Usher Syndrome Company Details
        11.5.2 Usher Syndrome Business Overview
        11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
        11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.5.5 Usher Syndrome Recent Developments
    11.6 Takeda Pharmaceutical
        11.6.1 Takeda Pharmaceutical Company Details
        11.6.2 Takeda Pharmaceutical Business Overview
        11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
        11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.6.5 Takeda Pharmaceutical Recent Developments
    11.7 Roche
        11.7.1 Roche Company Details
        11.7.2 Roche Business Overview
        11.7.3 Roche Ophthalmology Disorders Drug Introduction
        11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.7.5 Roche Recent Developments
    11.8 Pfizer
        11.8.1 Pfizer Company Details
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
        11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.8.5 Pfizer Recent Developments
    11.9 Allergan
        11.9.1 Allergan Company Details
        11.9.2 Allergan Business Overview
        11.9.3 Allergan Ophthalmology Disorders Drug Introduction
        11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.9.5 Allergan Recent Developments
    11.10 Gilead Sciences
        11.10.1 Gilead Sciences Company Details
        11.10.2 Gilead Sciences Business Overview
        11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
        11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.10.5 Gilead Sciences Recent Developments
    11.11 Kubota Pharmaceutical
        11.11.1 Kubota Pharmaceutical Company Details
        11.11.2 Kubota Pharmaceutical Business Overview
        11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
        11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.11.5 Kubota Pharmaceutical Recent Developments
    11.12 Alkeus Pharmaceuticals
        11.12.1 Alkeus Pharmaceuticals Company Details
        11.12.2 Alkeus Pharmaceuticals Business Overview
        11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.12.5 Alkeus Pharmaceuticals Recent Developments
    11.13 Astellas Pharma
        11.13.1 Astellas Pharma Company Details
        11.13.2 Astellas Pharma Business Overview
        11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
        11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.13.5 Astellas Pharma Recent Developments
    11.14 Ferrer Corporate
        11.14.1 Ferrer Corporate Company Details
        11.14.2 Ferrer Corporate Business Overview
        11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
        11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.14.5 Ferrer Corporate Recent Developments
    11.15 Amgen Inc
        11.15.1 Amgen Inc Company Details
        11.15.2 Amgen Inc Business Overview
        11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
        11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.15.5 Amgen Inc Recent Developments
    11.16 Editas Medicine Inc
        11.16.1 Editas Medicine Inc Company Details
        11.16.2 Editas Medicine Inc Business Overview
        11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
        11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.16.5 Editas Medicine Inc Recent Developments
    11.17 ProQR Therapeutics NV
        11.17.1 ProQR Therapeutics NV Company Details
        11.17.2 ProQR Therapeutics NV Business Overview
        11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
        11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.17.5 ProQR Therapeutics NV Recent Developments
    11.18 ReNeuron
        11.18.1 ReNeuron Company Details
        11.18.2 ReNeuron Business Overview
        11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
        11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.18.5 ReNeuron Recent Developments
    11.19 Amarantus BioScience
        11.19.1 Amarantus BioScience Company Details
        11.19.2 Amarantus BioScience Business Overview
        11.19.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
        11.19.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.19.5 Amarantus BioScience Recent Developments
    11.20 Ocugen
        11.20.1 Ocugen Company Details
        11.20.2 Ocugen Business Overview
        11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
        11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.20.5 Ocugen Recent Developments
    11.21 ReGenX Biosciences
        11.21.1 ReGenX Biosciences Company Details
        11.21.2 ReGenX Biosciences Business Overview
        11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
        11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.21.5 ReGenX Biosciences Recent Developments
    11.22 Sucampo Pharmaceuticals
        11.22.1 Sucampo Pharmaceuticals Company Details
        11.22.2 Sucampo Pharmaceuticals Business Overview
        11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.22.5 Sucampo Pharmaceuticals Recent Developments
    11.23 Orphagen Pharmaceuticals
        11.23.1 Orphagen Pharmaceuticals Company Details
        11.23.2 Orphagen Pharmaceuticals Business Overview
        11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.23.5 Orphagen Pharmaceuticals Recent Developments
    11.24 Okuvision
        11.24.1 Okuvision Company Details
        11.24.2 Okuvision Business Overview
        11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
        11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.24.5 Okuvision Recent Developments
    11.25 Second Sight Medical
        11.25.1 Second Sight Medical Company Details
        11.25.2 Second Sight Medical Business Overview
        11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
        11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.25.5 Second Sight Medical Recent Developments
    11.26 Acucela
        11.26.1 Acucela Company Details
        11.26.2 Acucela Business Overview
        11.26.3 Acucela Ophthalmology Disorders Drug Introduction
        11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.26.5 Acucela Recent Developments
    11.27 Stealth BioTherapeutics
        11.27.1 Stealth BioTherapeutics Company Details
        11.27.2 Stealth BioTherapeutics Business Overview
        11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
        11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.27.5 Stealth BioTherapeutics Recent Developments
    11.28 Sun Pharma Advanced Research Company
        11.28.1 Sun Pharma Advanced Research Company Company Details
        11.28.2 Sun Pharma Advanced Research Company Business Overview
        11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
        11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.28.5 Sun Pharma Advanced Research Company Recent Developments
    11.29 AmpliPhi Biosciences
        11.29.1 AmpliPhi Biosciences Company Details
        11.29.2 AmpliPhi Biosciences Business Overview
        11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
        11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.29.5 AmpliPhi Biosciences Recent Developments
    11.30 Applied Genetic Technologies
        11.30.1 Applied Genetic Technologies Company Details
        11.30.2 Applied Genetic Technologies Business Overview
        11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
        11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.30.5 Applied Genetic Technologies Recent Developments
    11.31 Asklepios BioPharmaceutical
        11.31.1 Asklepios BioPharmaceutical Company Details
        11.31.2 Asklepios BioPharmaceutical Business Overview
        11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
        11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.31.5 Asklepios BioPharmaceutical Recent Developments
    11.32 Biovista
        11.32.1 Biovista Company Details
        11.32.2 Biovista Business Overview
        11.32.3 Biovista Ophthalmology Disorders Drug Introduction
        11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.32.5 Biovista Recent Developments
    11.33 Spark Therapeutics
        11.33.1 Spark Therapeutics Company Details
        11.33.2 Spark Therapeutics Business Overview
        11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
        11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.33.5 Spark Therapeutics Recent Developments
    11.34 Caladrius Biosciences
        11.34.1 Caladrius Biosciences Company Details
        11.34.2 Caladrius Biosciences Business Overview
        11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
        11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.34.5 Caladrius Biosciences Recent Developments
    11.35 Dompe Farmaceutici
        11.35.1 Dompe Farmaceutici Company Details
        11.35.2 Dompe Farmaceutici Business Overview
        11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
        11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.35.5 Dompe Farmaceutici Recent Developments
    11.36 Dormant Projects
        11.36.1 Dormant Projects Company Details
        11.36.2 Dormant Projects Business Overview
        11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
        11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.36.5 Dormant Projects Recent Developments
    11.37 Grupo Ferrer Internacional
        11.37.1 Grupo Ferrer Internacional Company Details
        11.37.2 Grupo Ferrer Internacional Business Overview
        11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
        11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.37.5 Grupo Ferrer Internacional Recent Developments
    11.38 ID Pharma
        11.38.1 ID Pharma Company Details
        11.38.2 ID Pharma Business Overview
        11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
        11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.38.5 ID Pharma Recent Developments
    11.39 InFlectis BioScience
        11.39.1 InFlectis BioScience Company Details
        11.39.2 InFlectis BioScience Business Overview
        11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
        11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.39.5 InFlectis BioScience Recent Developments
    11.40 Ionis Pharmaceuticals
        11.40.1 Ionis Pharmaceuticals Company Details
        11.40.2 Ionis Pharmaceuticals Business Overview
        11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.40.5 Ionis Pharmaceuticals Recent Developments
    11.41 Ixchel Pharma
    11.42 Khondrion
    11.43 Mimetogen Pharmaceuticals
    11.44 Mitotech
    11.45 M's Science
    11.46 Nanovector
    11.47 SanBio
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
List of Tables
    Table 1. Global Ophthalmology Disorders Drug Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Oral
    Table 3. Key Players of Injection
    Table 4. Key Players of External Use
    Table 5. Global Ophthalmology Disorders Drug Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 6. Global Ophthalmology Disorders Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Ophthalmology Disorders Drug Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Ophthalmology Disorders Drug Market Share by Region (2017-2022)
    Table 9. Global Ophthalmology Disorders Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Ophthalmology Disorders Drug Market Share by Region (2023-2028)
    Table 11. Ophthalmology Disorders Drug Market Trends
    Table 12. Ophthalmology Disorders Drug Market Drivers
    Table 13. Ophthalmology Disorders Drug Market Challenges
    Table 14. Ophthalmology Disorders Drug Market Restraints
    Table 15. Global Ophthalmology Disorders Drug Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Ophthalmology Disorders Drug Revenue Share by Players (2017-2022)
    Table 17. Global Top Ophthalmology Disorders Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmology Disorders Drug as of 2021)
    Table 18. Ranking of Global Top Ophthalmology Disorders Drug Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Ophthalmology Disorders Drug Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Ophthalmology Disorders Drug Product Solution and Service
    Table 22. Date of Enter into Ophthalmology Disorders Drug Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Ophthalmology Disorders Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2017-2022)
    Table 26. Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Ophthalmology Disorders Drug Revenue Market Share by Type (2023-2028)
    Table 28. Global Ophthalmology Disorders Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Ophthalmology Disorders Drug Revenue Share by Application (2017-2022)
    Table 30. Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Ophthalmology Disorders Drug Revenue Share by Application (2023-2028)
    Table 32. North America Ophthalmology Disorders Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 33. North America Ophthalmology Disorders Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 34. North America Ophthalmology Disorders Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 35. North America Ophthalmology Disorders Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 36. North America Ophthalmology Disorders Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 37. North America Ophthalmology Disorders Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Europe Ophthalmology Disorders Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 39. Europe Ophthalmology Disorders Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 40. Europe Ophthalmology Disorders Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 41. Europe Ophthalmology Disorders Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 42. Europe Ophthalmology Disorders Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Europe Ophthalmology Disorders Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Ophthalmology Disorders Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Ophthalmology Disorders Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Ophthalmology Disorders Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Ophthalmology Disorders Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Ophthalmology Disorders Drug Market Size by Region (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Ophthalmology Disorders Drug Market Size by Region (2023-2028) & (US$ Million)
    Table 50. Latin America Ophthalmology Disorders Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Ophthalmology Disorders Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Ophthalmology Disorders Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Latin America Ophthalmology Disorders Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Latin America Ophthalmology Disorders Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Ophthalmology Disorders Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Ophthalmology Disorders Drug Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Ophthalmology Disorders Drug Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Ophthalmology Disorders Drug Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Ophthalmology Disorders Drug Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Ophthalmology Disorders Drug Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Ophthalmology Disorders Drug Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Sanofi Company Details
    Table 63. Sanofi Business Overview
    Table 64. Sanofi Ophthalmology Disorders Drug Product
    Table 65. Sanofi Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 66. Sanofi Recent Developments
    Table 67. Bayer Company Details
    Table 68. Bayer Business Overview
    Table 69. Bayer Ophthalmology Disorders Drug Product
    Table 70. Bayer Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 71. Bayer Recent Developments
    Table 72. Bausch + Lomb Company Details
    Table 73. Bausch + Lomb Business Overview
    Table 74. Bausch + Lomb Ophthalmology Disorders Drug Product
    Table 75. Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 76. Bausch + Lomb Recent Developments
    Table 77. Novartis Company Details
    Table 78. Novartis Business Overview
    Table 79. Novartis Ophthalmology Disorders Drug Product
    Table 80. Novartis Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 81. Novartis Recent Developments
    Table 82. Usher Syndrome Company Details
    Table 83. Usher Syndrome Business Overview
    Table 84. Usher Syndrome Ophthalmology Disorders Drug Product
    Table 85. Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 86. Usher Syndrome Recent Developments
    Table 87. Takeda Pharmaceutical Company Details
    Table 88. Takeda Pharmaceutical Business Overview
    Table 89. Takeda Pharmaceutical Ophthalmology Disorders Drug Product
    Table 90. Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 91. Takeda Pharmaceutical Recent Developments
    Table 92. Roche Company Details
    Table 93. Roche Business Overview
    Table 94. Roche Ophthalmology Disorders Drug Product
    Table 95. Roche Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 96. Roche Recent Developments
    Table 97. Pfizer Company Details
    Table 98. Pfizer Business Overview
    Table 99. Pfizer Ophthalmology Disorders Drug Product
    Table 100. Pfizer Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 101. Pfizer Recent Developments
    Table 102. Allergan Company Details
    Table 103. Allergan Business Overview
    Table 104. Allergan Ophthalmology Disorders Drug Product
    Table 105. Allergan Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 106. Allergan Recent Developments
    Table 107. Gilead Sciences Company Details
    Table 108. Gilead Sciences Business Overview
    Table 109. Gilead Sciences Ophthalmology Disorders Drug Product
    Table 110. Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 111. Gilead Sciences Recent Developments
    Table 112. Kubota Pharmaceutical Company Details
    Table 113. Kubota Pharmaceutical Business Overview
    Table 114. Kubota Pharmaceutical Ophthalmology Disorders Drug Product
    Table 115. Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 116. Kubota Pharmaceutical Recent Developments
    Table 117. Alkeus Pharmaceuticals Company Details
    Table 118. Alkeus Pharmaceuticals Business Overview
    Table 119. Alkeus Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 120. Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 121. Alkeus Pharmaceuticals Recent Developments
    Table 122. Astellas Pharma Company Details
    Table 123. Astellas Pharma Business Overview
    Table 124. Astellas Pharma Ophthalmology Disorders Drug Product
    Table 125. Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 126. Astellas Pharma Recent Developments
    Table 127. Ferrer Corporate Company Details
    Table 128. Ferrer Corporate Business Overview
    Table 129. Ferrer Corporate Ophthalmology Disorders Drug Product
    Table 130. Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 131. Ferrer Corporate Recent Developments
    Table 132. Amgen Inc Company Details
    Table 133. Amgen Inc Business Overview
    Table 134. Amgen Inc Ophthalmology Disorders Drug Product
    Table 135. Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 136. Amgen Inc Recent Developments
    Table 137. Editas Medicine Inc Company Details
    Table 138. Editas Medicine Inc Business Overview
    Table 139. Editas Medicine Inc Ophthalmology Disorders Drug Product
    Table 140. Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 141. Editas Medicine Inc Recent Developments
    Table 142. ProQR Therapeutics NV Company Details
    Table 143. ProQR Therapeutics NV Business Overview
    Table 144. ProQR Therapeutics NV Ophthalmology Disorders Drug Product
    Table 145. ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 146. ProQR Therapeutics NV Recent Developments
    Table 147. ReNeuron Company Details
    Table 148. ReNeuron Business Overview
    Table 149. ReNeuron Ophthalmology Disorders Drug Product
    Table 150. ReNeuron Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 151. ReNeuron Recent Developments
    Table 152. Amarantus BioScience Company Details
    Table 153. Amarantus BioScience Business Overview
    Table 154. Amarantus BioScience Ophthalmology Disorders Drug Product
    Table 155. Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 156. Amarantus BioScience Recent Developments
    Table 157. Ocugen Company Details
    Table 158. Ocugen Business Overview
    Table 159. Ocugen Ophthalmology Disorders Drug Product
    Table 160. Ocugen Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 161. Ocugen Recent Developments
    Table 162. ReGenX Biosciences Company Details
    Table 163. ReGenX Biosciences Business Overview
    Table 164. ReGenX Biosciences Ophthalmology Disorders Drug Product
    Table 165. ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 166. ReGenX Biosciences Recent Developments
    Table 167. Sucampo Pharmaceuticals Company Details
    Table 168. Sucampo Pharmaceuticals Business Overview
    Table 169. Sucampo Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 170. Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 171. Sucampo Pharmaceuticals Recent Developments
    Table 172. Orphagen Pharmaceuticals Company Details
    Table 173. Orphagen Pharmaceuticals Business Overview
    Table 174. Orphagen Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 175. Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 176. Orphagen Pharmaceuticals Recent Developments
    Table 177. Okuvision Company Details
    Table 178. Okuvision Business Overview
    Table 179. Okuvision Ophthalmology Disorders Drug Product
    Table 180. Okuvision Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 181. Okuvision Recent Developments
    Table 182. Second Sight Medical Company Details
    Table 183. Second Sight Medical Business Overview
    Table 184. Second Sight Medical Ophthalmology Disorders Drug Product
    Table 185. Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 186. Second Sight Medical Recent Developments
    Table 187. Acucela Company Details
    Table 188. Acucela Business Overview
    Table 189. Acucela Ophthalmology Disorders Drug Product
    Table 190. Acucela Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 191. Acucela Recent Developments
    Table 192. Stealth BioTherapeutics Company Details
    Table 193. Stealth BioTherapeutics Business Overview
    Table 194. Stealth BioTherapeutics Ophthalmology Disorders Drug Product
    Table 195. Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 196. Stealth BioTherapeutics Recent Developments
    Table 197. Sun Pharma Advanced Research Company Company Details
    Table 198. Sun Pharma Advanced Research Company Business Overview
    Table 199. Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Product
    Table 200. Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 201. Sun Pharma Advanced Research Company Recent Developments
    Table 202. AmpliPhi Biosciences Company Details
    Table 203. AmpliPhi Biosciences Business Overview
    Table 204. AmpliPhi Biosciences Ophthalmology Disorders Drug Product
    Table 205. AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 206. AmpliPhi Biosciences Recent Developments
    Table 207. Applied Genetic Technologies Company Details
    Table 208. Applied Genetic Technologies Business Overview
    Table 209. Applied Genetic Technologies Ophthalmology Disorders Drug Product
    Table 210. Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 211. Applied Genetic Technologies Recent Developments
    Table 212. Asklepios BioPharmaceutical Company Details
    Table 213. Asklepios BioPharmaceutical Business Overview
    Table 214. Asklepios BioPharmaceutical Ophthalmology Disorders Drug Product
    Table 215. Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 216. Asklepios BioPharmaceutical Recent Developments
    Table 217. Biovista Company Details
    Table 218. Biovista Business Overview
    Table 219. Biovista Ophthalmology Disorders Drug Product
    Table 220. Biovista Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 221. Biovista Recent Developments
    Table 222. Spark Therapeutics Company Details
    Table 223. Spark Therapeutics Business Overview
    Table 224. Spark Therapeutics Ophthalmology Disorders Drug Product
    Table 225. Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 226. Spark Therapeutics Recent Developments
    Table 227. Caladrius Biosciences Company Details
    Table 228. Caladrius Biosciences Business Overview
    Table 229. Caladrius Biosciences Ophthalmology Disorders Drug Product
    Table 230. Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 231. Caladrius Biosciences Recent Developments
    Table 232. Dompe Farmaceutici Company Details
    Table 233. Dompe Farmaceutici Business Overview
    Table 234. Dompe Farmaceutici Ophthalmology Disorders Drug Product
    Table 235. Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 236. Dompe Farmaceutici Recent Developments
    Table 237. Dormant Projects Company Details
    Table 238. Dormant Projects Business Overview
    Table 239. Dormant Projects Ophthalmology Disorders Drug Product
    Table 240. Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 241. Dormant Projects Recent Development
    Table 242. Grupo Ferrer Internacional Company Details
    Table 243. Grupo Ferrer Internacional Business Overview
    Table 244. Grupo Ferrer Internacional Ophthalmology Disorders Drug Product
    Table 245. Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 246. Grupo Ferrer Internacional Recent Development
    Table 247. ID Pharma Company Details
    Table 248. ID Pharma Business Overview
    Table 249. ID Pharma Ophthalmology Disorders Drug Product
    Table 250. ID Pharma Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 251. ID Pharma Recent Development
    Table 252. InFlectis BioScience Company Details
    Table 253. InFlectis BioScience Business Overview
    Table 254. InFlectis BioScience Ophthalmology Disorders Drug Product
    Table 255. InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 256. InFlectis BioScience Recent Development
    Table 257. Ionis Pharmaceuticals Company Details
    Table 258. Ionis Pharmaceuticals Business Overview
    Table 259. Ionis Pharmaceuticals Ophthalmology Disorders Drug Product
    Table 260. Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022) & (US$ Million)
    Table 261. Ionis Pharmaceuticals Recent Development
    Table 262. Research Programs/Design for This Report
    Table 263. Key Data Information from Secondary Sources
    Table 264. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Ophthalmology Disorders Drug Market Share by Type: 2021 VS 2028
    Figure 2. Oral Features
    Figure 3. Injection Features
    Figure 4. External Use Features
    Figure 5. Global Ophthalmology Disorders Drug Market Share by Application: 2021 VS 2028
    Figure 6. Juvenile Macular Degeneration (Stargardt Disease) Case Studies
    Figure 7. Leber Congenital Amaurosis (LCA) Case Studies
    Figure 8. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Case Studies
    Figure 9. Usher Syndrome Case Studies
    Figure 10. Retinitis Pigmentosa (Retinitis) Case Studies
    Figure 11. Ophthalmology Disorders Drug Report Years Considered
    Figure 12. Global Ophthalmology Disorders Drug Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Ophthalmology Disorders Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Ophthalmology Disorders Drug Market Share by Region: 2021 VS 2028
    Figure 15. Global Ophthalmology Disorders Drug Market Share by Players in 2021
    Figure 16. Global Top Ophthalmology Disorders Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmology Disorders Drug as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Ophthalmology Disorders Drug Revenue in 2021
    Figure 18. North America Ophthalmology Disorders Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 19. North America Ophthalmology Disorders Drug Market Size Market Share by Type (2017-2028)
    Figure 20. North America Ophthalmology Disorders Drug Market Size Market Share by Application (2017-2028)
    Figure 21. North America Ophthalmology Disorders Drug Market Size Share by Country (2017-2028)
    Figure 22. United States Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Canada Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Ophthalmology Disorders Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 25. Europe Ophthalmology Disorders Drug Market Size Market Share by Type (2017-2028)
    Figure 26. Europe Ophthalmology Disorders Drug Market Size Market Share by Application (2017-2028)
    Figure 27. Europe Ophthalmology Disorders Drug Market Size Share by Country (2017-2028)
    Figure 28. Germany Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. France Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. U.K. Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Italy Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Russia Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Nordic Countries Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Ophthalmology Disorders Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 35. Asia Pacific Ophthalmology Disorders Drug Market Size Market Share by Type (2017-2028)
    Figure 36. Asia Pacific Ophthalmology Disorders Drug Market Size Market Share by Application (2017-2028)
    Figure 37. Asia Pacific Ophthalmology Disorders Drug Market Size Share by Region (2017-2028)
    Figure 38. China Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Japan Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. South Korea Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Southeast Asia Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. India Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Australia Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 44. Latin America Ophthalmology Disorders Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 45. Latin America Ophthalmology Disorders Drug Market Size Market Share by Type (2017-2028)
    Figure 46. Latin America Ophthalmology Disorders Drug Market Size Market Share by Application (2017-2028)
    Figure 47. Latin America Ophthalmology Disorders Drug Market Size Share by Country (2017-2028)
    Figure 48. Mexico Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Brazil Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Ophthalmology Disorders Drug Market Size YoY (2017-2028) & (US$ Million)
    Figure 51. Middle East and Africa Ophthalmology Disorders Drug Market Size Market Share by Type (2017-2028)
    Figure 52. Middle East and Africa Ophthalmology Disorders Drug Market Size Market Share by Application (2017-2028)
    Figure 53. Middle East and Africa Ophthalmology Disorders Drug Market Size Share by Country (2017-2028)
    Figure 54. Turkey Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Saudi Arabia Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. UAE Ophthalmology Disorders Drug Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Sanofi Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 58. Bayer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 59. Bausch + Lomb Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 60. Novartis Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 61. Usher Syndrome Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 62. Takeda Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 63. Roche Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 64. Pfizer Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 65. Allergan Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 66. Gilead Sciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 67. Kubota Pharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 68. Alkeus Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 69. Astellas Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 70. Ferrer Corporate Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 71. Amgen Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 72. Editas Medicine Inc Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 73. ProQR Therapeutics NV Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 74. ReNeuron Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 75. Amarantus BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 76. Ocugen Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 77. ReGenX Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 78. Sucampo Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 79. Orphagen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 80. Okuvision Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 81. Second Sight Medical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 82. Acucela Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 83. Stealth BioTherapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 84. Sun Pharma Advanced Research Company Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 85. AmpliPhi Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 86. Applied Genetic Technologies Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 87. Asklepios BioPharmaceutical Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 88. Biovista Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 89. Spark Therapeutics Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 90. Caladrius Biosciences Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 91. Dompe Farmaceutici Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 92. Dormant Projects Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 93. Grupo Ferrer Internacional Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 94. ID Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 95. InFlectis BioScience Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 96. Ionis Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 97. Ixchel Pharma Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 98. Khondrion Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 99. Mimetogen Pharmaceuticals Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 100. Mitotech Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 101. M's Science Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 102. Nanovector Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 103. SanBio Revenue Growth Rate in Ophthalmology Disorders Drug Business (2017-2022)
    Figure 104. Bottom-up and Top-down Approaches for This Report
    Figure 105. Data Triangulation
    Figure 106. Key Executives Interviewed